​

Hologic (HOLX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HOLX Stock Forecast

Hologic stock forecast is as follows: an average price target of $74.20 (represents a 3.56% upside from HOLX’s last price of $71.65) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.

HOLX Price Target

The average price target for Hologic (HOLX) is $74.20 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $33.00. This represents a potential 3.56% upside from HOLX's last price of $71.65.

HOLX Analyst Ratings

Buy

According to 16 Wall Street analysts, Hologic's rating consensus is 'Buy'. The analyst rating breakdown for HOLX stock is 0 'Strong Buy' (0.00%), 11 'Buy' (68.75%), 5 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Hologic Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Anthony PetroneMizuho Securities$87.00$78.8010.41%21.42%
Oct 04, 2024Anthony PetroneMizuho Securities$90.00$79.6313.02%25.61%
Oct 01, 2024Patrick DonnellyCitigroup$85.00$81.464.35%18.63%
Jul 30, 2024Mike MatsonNeedham$90.00$80.8411.33%25.61%
Jul 02, 2024Vijay KumarEvercore ISI$76.00$74.102.56%6.07%
Jun 27, 2024Ian ZaffinoOppenheimer$33.00$73.06-54.83%-53.94%
May 09, 2024David ToungArgus Research$95.00$75.8625.23%32.59%
Feb 02, 2023Cowen & Co.$95.00$83.7713.41%32.59%
Jan 10, 2023Wells Fargo$80.00$81.07-1.32%11.65%
Dec 07, 2022RBC Capital$75.00$74.221.05%4.68%
Jul 28, 2022Morgan Stanley$70.00$70.86-1.21%-2.30%
Jul 28, 2022Raymond James$80.00$71.3112.19%11.65%
May 17, 2022Leerink Partners$85.00$77.2210.08%18.63%
Apr 28, 2022Citigroup$75.00$68.988.73%4.68%
Apr 28, 2022Raymond James$83.00$68.4221.31%15.84%
Apr 28, 2022Leerink Partners$82.00$70.8415.75%14.45%
Apr 25, 2022Wells Fargo$75.00$73.931.45%4.68%
Apr 06, 2022Vijay KumarEvercore ISI$80.00$78.342.12%11.65%
Dec 09, 2021Anthony PetroneJefferies$95.00$75.1926.35%32.59%
Apr 29, 2021Michael LasserUBS$77.00$66.2316.26%7.47%

The latest Hologic stock forecast, released on Nov 05, 2024 by Anthony Petrone from Mizuho Securities, set a price target of $87.00, which represents a 10.41% increase from the stock price at the time of the forecast ($78.80), and a 21.42% increase from HOLX last price ($71.65).

Hologic Price Target by Period

1M3M12M
# Anlaysts-37
Avg Price Target-$87.33$79.43
Last Closing Price$71.65$71.65$71.65
Upside/Downside-100.00%21.88%10.86%

In the current month, the average price target of Hologic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Hologic's last price of $71.65. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024NeedhamBuyBuyHold
Oct 14, 2024William BlairCautiousCautiousHold
Oct 04, 2024StephensSector PerformSector PerformHold
Oct 01, 2024Evercore ISIPositivePositiveHold
Oct 01, 2024CitigroupBuyNeutralDowngrade
Sep 17, 2024NeedhamBuyBuyHold
Jul 30, 2024NeedhamBuyBuyHold
Jul 30, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 30, 2024Keefe, Bruyette & WoodsOverweightOverweightHold
Jul 30, 2024RBC CapitalBuyBuyHold
Jul 30, 2024Wells FargoOverweightOverweightHold
Jul 30, 2024BenchmarkBuyBuyHold
Jul 30, 2024SusquehannaPositivePositiveHold
Jul 30, 2024StephensSector PerformSector PerformHold
Jul 30, 2024BTIGNeutralNeutralHold
Jul 30, 2024RBC CapitalSector PerformSector PerformHold
Jun 27, 2024OppenheimerOutperformInitialise
Jun 27, 2024StephensBuyBuyHold
Jun 26, 2024StephensOverweightInitialise
May 03, 2024NeedhamBuyBuyHold
Apr 03, 2024CitigroupNeutralBuyUpgrade
Feb 02, 2024NeedhamBuyBuyHold
Jul 14, 2023NeedhamBuyUpgrade
Feb 02, 2023Cowen & Co.OutperformOutperformHold
Feb 02, 2023CitigroupNeutralNeutralHold
Jan 10, 2023Wells FargoEqual-WeightEqual-WeightHold
Dec 07, 2022RBC CapitalSector PerformInitialise
Jul 28, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 28, 2022Raymond JamesOutperformOutperformHold
Apr 28, 2022CitigroupNeutralNeutralHold
Apr 28, 2022Raymond JamesOutperformOutperformHold
Apr 28, 2022SVB LeerinkOutperformOutperformHold

Hologic's last stock rating was published by Needham on Oct 14, 2024. The company gave HOLX a "Buy" rating, the same as its previous rate.

Hologic Financial Forecast

Hologic Revenue Forecast

Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Revenue---------------$277.90M$945.30M$984.40M$1.03B$1.07B$953.30M$1.00B$1.44B$1.47B$1.32B$1.17B$1.54B$1.61B$1.35B$822.90M
Avg Forecast$1.14B$1.16B$1.13B$1.12B$1.10B$1.12B$1.10B$1.09B$1.05B$1.06B$1.04B$1.03B$978.26M$1.00B$1.00B$989.32M$940.00M$960.25M$956.44M$1.00B$862.09M$903.31M$1.29B$1.19B$1.04B$1.04B$1.54B$1.40B$1.12B$616.70M
High Forecast$1.17B$1.19B$1.16B$1.15B$1.13B$1.14B$1.12B$1.12B$1.07B$1.08B$1.05B$1.05B$978.71M$1.00B$1.00B$1.02B$951.96M$984.30M$980.40M$1.03B$862.09M$903.31M$1.29B$1.19B$1.04B$1.04B$1.54B$1.40B$1.12B$616.70M
Low Forecast$1.13B$1.15B$1.12B$1.11B$1.09B$1.10B$1.08B$1.08B$1.03B$1.04B$1.02B$1.01B$977.81M$1.00B$1.00B$976.49M$927.37M$947.81M$944.05M$991.74M$862.09M$903.31M$1.29B$1.19B$1.04B$1.04B$1.54B$1.40B$1.12B$616.70M
# Analysts65585510644111155561411766767107121288
Surprise %---------------0.28%1.01%1.03%1.07%1.07%1.11%1.11%1.11%1.23%1.26%1.13%1.00%1.15%1.20%1.33%

Hologic's average Quarter revenue forecast for Mar 24 based on 5 analysts is $1.00B, with a low forecast of $1.00B, and a high forecast of $1.00B. HOLX's average Quarter revenue forecast represents a 260.47% increase compared to the company's last Quarter revenue of $277.90M (Dec 23).

Hologic EBITDA Forecast

Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts65585510644111155561411766767107121288
EBITDA---------------$198.20M$305.50M$1.40M$376.70M$354.20M$208.70M$345.90M$702.90M$752.40M$450.90M$463.80M$883.90M$984.60M$662.80M$290.40M
Avg Forecast$443.09M$450.90M$438.70M$435.59M$426.60M$432.05M$424.69M$422.04M$406.04M$409.81M$401.57M$397.18M$378.82M$387.93M$600.84M$383.10M$364.00M$371.84M$546.22M$560.13M$314.18M$329.21M$496.56M$434.78M$380.11M$378.44M$907.78M$511.15M$408.02M$224.75M
High Forecast$454.19M$462.19M$449.69M$446.51M$437.29M$442.87M$435.33M$432.61M$416.21M$420.08M$405.43M$407.13M$378.99M$387.93M$721.01M$393.52M$368.63M$381.16M$655.46M$672.16M$314.18M$329.21M$595.88M$434.78M$380.11M$378.44M$1.09B$511.15M$408.02M$224.75M
Low Forecast$437.35M$445.06M$433.02M$429.95M$421.07M$426.45M$419.19M$416.57M$400.78M$404.50M$396.37M$392.04M$378.64M$387.93M$480.67M$378.13M$359.11M$367.03M$436.98M$448.11M$314.18M$329.21M$397.25M$434.78M$380.11M$378.44M$726.22M$511.15M$408.02M$224.75M
Surprise %---------------0.52%0.84%0.00%0.69%0.63%0.66%1.05%1.42%1.73%1.19%1.23%0.97%1.93%1.62%1.29%

5 analysts predict HOLX's average Quarter EBITDA for Mar 24 to be $600.84M, with a high of $721.01M and a low of $480.67M. This is 203.15% upper than Hologic's previous annual EBITDA (Dec 23) of $198.20M.

Hologic Net Income Forecast

Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts65585510644111155561411766767107121288
Net Income---------------$246.50M$90.60M$-40.50M$218.50M$187.40M$118.70M$228.40M$455.70M$499.20M$328.80M$268.40M$619.90M$654.40M$495.00M$137.90M
Avg Forecast$317.76M$321.98M$292.25M$284.70M$282.46M$281.63M$271.76M$264.76M$259.24M$261.03M$248.06M$238.14M$239.08M$240.07M$389.42M$224.15M$198.27M$209.83M$354.02M$370.06M$147.67M$168.01M$321.84M$313.08M$237.34M$264.70M$627.00M$512.54M$290.72M$91.25M
High Forecast$328.11M$332.47M$301.77M$293.98M$291.66M$290.81M$280.61M$273.38M$267.69M$269.54M$256.14M$240.49M$239.10M$240.11M$467.31M$231.23M$207.71M$216.67M$424.83M$444.07M$147.67M$168.01M$386.21M$313.08M$237.34M$264.70M$752.40M$512.54M$290.72M$91.25M
Low Forecast$312.41M$316.56M$287.33M$279.91M$277.71M$276.89M$267.19M$260.30M$254.88M$256.64M$245.74M$235.78M$239.06M$240.02M$311.54M$219.43M$188.83M$206.30M$283.22M$296.05M$147.67M$168.01M$257.47M$313.08M$237.34M$264.70M$501.60M$512.54M$290.72M$91.25M
Surprise %---------------1.10%0.46%-0.19%0.62%0.51%0.80%1.36%1.42%1.59%1.39%1.01%0.99%1.28%1.70%1.51%

Hologic's average Quarter net income forecast for Mar 24 is $389.42M, with a range of $311.54M to $467.31M. HOLX's average Quarter net income forecast represents a 57.98% increase compared to the company's last Quarter net income of $246.50M (Dec 23).

Hologic SG&A Forecast

Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts65585510644111155561411766767107121288
SG&A---------------$260.70M$232.40M$240.00M$243.20M$272.00M$256.50M$244.20M$271.90M$265.30M$294.50M$260.00M$220.40M$219.50M$221.30M$208.80M
Avg Forecast$252.76M$257.21M$250.25M$248.48M$243.35M$246.46M$242.26M$240.75M$231.62M$233.77M$229.07M$226.57M$216.09M$221.29M$232.36M$218.53M$207.64M$212.11M$211.23M$196.67M$193.81M$203.08M$192.03M$268.21M$234.48M$233.45M$222.92M$315.32M$251.70M$138.64M
High Forecast$259.09M$263.65M$256.52M$254.70M$249.45M$252.63M$248.33M$246.78M$237.42M$239.63M$231.27M$232.24M$216.19M$221.29M$278.83M$224.48M$210.28M$217.43M$253.48M$236.00M$193.81M$203.08M$230.44M$268.21M$234.48M$233.45M$267.51M$315.32M$251.70M$138.64M
Low Forecast$249.48M$253.88M$247.01M$245.26M$240.20M$243.26M$239.12M$237.63M$228.62M$230.74M$226.10M$223.63M$215.99M$221.29M$185.88M$215.70M$204.85M$209.37M$168.99M$157.34M$193.81M$203.08M$153.62M$268.21M$234.48M$233.45M$178.34M$315.32M$251.70M$138.64M
Surprise %---------------1.19%1.12%1.13%1.15%1.38%1.32%1.20%1.42%0.99%1.26%1.11%0.99%0.70%0.88%1.51%

Hologic's average Quarter SG&A projection for Mar 24 is $232.36M, based on 5 Wall Street analysts, with a range of $185.88M to $278.83M. The forecast indicates a -10.87% fall compared to HOLX last annual SG&A of $260.70M (Dec 23).

Hologic EPS Forecast

Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts65585510644111155561411766767107121288
EPS----------------$0.37$-0.16$0.88$0.76$0.47$0.91$1.81$1.97$1.29$1.05$2.40$2.53$1.90$0.53
Avg Forecast$1.35$1.36$1.24$1.21$1.20$1.19$1.15$1.12$1.10$1.11$1.05$1.01$1.01$1.02$0.98$0.95$0.84$0.89$0.88$0.91$0.62$0.71$1.60$1.32$1.00$1.12$2.62$2.17$1.23$0.39
High Forecast$1.39$1.41$1.28$1.25$1.24$1.23$1.19$1.16$1.13$1.14$1.09$1.02$1.01$1.02$0.98$0.98$0.88$0.92$0.91$0.94$0.62$0.71$1.60$1.32$1.00$1.12$2.62$2.17$1.23$0.39
Low Forecast$1.32$1.34$1.22$1.19$1.18$1.17$1.13$1.10$1.08$1.09$1.04$1.00$1.01$1.02$0.98$0.93$0.80$0.87$0.86$0.90$0.62$0.71$1.60$1.32$1.00$1.12$2.62$2.17$1.23$0.39
Surprise %---------------0.00%0.44%-0.18%1.00%0.83%0.75%1.28%1.13%1.49%1.29%0.94%0.92%1.17%1.55%1.37%

According to 5 Wall Street analysts, Hologic's projected average Quarter EPS for Mar 24 is $0.98, with a low estimate of $0.98 and a high estimate of $0.98. This represents a 97680.00% increase compared to HOLX previous annual EPS of - (Dec 23).

Hologic Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TFXTeleflex$178.28$254.5042.75%Buy
ANGOAngioDynamics$9.26$13.0040.39%Buy
HAEHaemonetics$82.07$107.0030.38%Buy
BDXBecton, Dickinson and Company$225.64$278.7523.54%Buy
ATRAptarGroup$163.09$200.0022.63%Buy
COOCooper Companies$94.49$115.0021.71%Buy
ALCAlcon$85.54$104.0021.58%Buy
ICUIICU Medical$157.17$190.5021.21%Buy
WSTWest Pharmaceutical Services$334.26$393.0017.57%Buy
MMSIMerit Medical Systems$99.00$108.839.93%Buy
NVSTEnvista$19.24$20.295.46%Hold
HOLXHologic$72.26$74.202.68%Buy
RMDResMed$242.62$233.50-3.76%Hold

HOLX Forecast FAQ

Is Hologic a good buy?

Yes, according to 16 Wall Street analysts, Hologic (HOLX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 68.75% of HOLX's total ratings.

What is HOLX's price target?

Hologic (HOLX) average price target is $74.2 with a range of $33 to $90, implying a 3.56% from its last price of $71.65. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Hologic stock go up soon?

According to Wall Street analysts' prediction for HOLX stock, the company can go up by 3.56% (from the last price of $71.65 to the average price target of $74.2), up by 25.61% based on the highest stock price target, and down by -53.94% based on the lowest stock price target.

Can Hologic stock reach $110?

HOLX's average twelve months analyst stock price target of $74.2 does not support the claim that Hologic can reach $110 in the near future.

What are Hologic's analysts' financial forecasts?

Hologic's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $4.4B (high $4.51B, low $4.35B), average EBITDA is $1.71B (high $1.75B, low $1.68B), average net income is $1.1B (high $1.14B, low $1.08B), average SG&A $972.81M (high $997.18M, low $960.21M), and average EPS is $4.66 (high $4.82, low $4.59). HOLX's analysts financial forecasts for the fiscal year (Sep 2027) are as follows: average revenue is $4.57B (high $4.68B, low $4.51B), average EBITDA is $1.77B (high $1.81B, low $1.75B), average net income is $1.22B (high $1.26B, low $1.2B), average SG&A $1.01B (high $1.03B, low $995.63M), and average EPS is $5.16 (high $5.32, low $5.07).

Did the HOLX's actual financial results beat the analysts' financial forecasts?

Based on Hologic's last annual report (Sep 2023), the company's revenue was $4.03B, beating the average analysts forecast of $3.86B by 4.38%. Apple's EBITDA was $1.2B, missing the average prediction of $1.84B by -34.66%. The company's net income was $456M, missing the average estimation of $1.13B by -59.72%. Apple's SG&A was $987.6M, beating the average forecast of $827.66M by 19.32%. Lastly, the company's EPS was $1.85, missing the average prediction of $3.52 by -47.42%. In terms of the last quarterly report (Dec 2023), Hologic's revenue was $277.9M, missing the average analysts' forecast of $989.32M by -71.91%. The company's EBITDA was $198.2M, missing the average prediction of $383.1M by -48.26%. Hologic's net income was $246.5M, beating the average estimation of $224.15M by 9.97%. The company's SG&A was $260.7M, beating the average forecast of $218.53M by 19.29%. Lastly, the company's EPS was $0.001, missing the average prediction of $0.95 by -99.89%